Publication Name	World Journal of Hepatology
Manuscript ID	25575
Country	France

Received	2016-03-15 11:21
Peer-Review Started	2016-03-18 09:24
To Make the First Decision	2016-04-18 19:35
Return for Revision	2016-04-20 18:51
Revised
Second Decision	2016-10-21 10:21
Accepted by Journal Editor-in-Chief	2016-10-22 05:10
Accepted by Executive Editor-in-Chief	2016-11-02 15:53
Articles in Press	2016-11-02 15:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-12-12 09:59
Publish the Manuscript Online	2016-12-15 16:07

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Jean-Luc Raoul, Xavier Adhoute, Marine Gilabert and Julien Edeline
Funding Agency and Grant Number
Corresponding Author	Dr. Jean-Luc Raoul, Professor, Depart­ment of Medical Oncology, Paoli-Calmettes Institute, BP 156, 13273 Marseille, France. raouljl@ipc.unicancer.fr
Key Words	Tumor evaluation; Response evaluation criteria in solid tumors; Sorafenib; Hepatocellular carcinoma; Modified response evaluation criteria in solid tumors
Core Tip	The response rate of sorafenib in hepato-cellular carcinoma is low using standard parameters and is better assessed using new criteria based on tumor vascularization (European Association of the Study of the Liver criteria, modified response evaluation criteria in solid tumors). In case of minor progression, if sorafenib is well tolerated, knowing the predictors of post-progression survival will be of value in deciding whether to continue or stop sorafenib.
Publish Date	2016-12-15 16:07
Citation	Raoul JL, Adhoute X, Gilabert M, Edeline J. How to assess the efficacy or failure of targeted therapy: deciding when to stop sorafenib in hepatocellular carcinoma. World J Hepatol 2016; 8(35): 1541-1546
URL	http://www.wjgnet.com/1948-5182/full/v8/i35/1541.htm
DOI	http://dx.doi.org/10.4254/wjh.v8.i35.1541

Full Article (PDF)	WJH-8-1541.pdf
Full Article (Word)	WJH-8-1541.doc
Manuscript File	25575-Review.docx
Answering Reviewers	25575-Answering reviewers.pdf
Audio Core Tip	25575-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	25575-Conflict-of-interest statement.pdf
Copyright License Agreement	25575-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	25575-Language certificate.pdf
Peer-review Report	25575-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	25575-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	25575-Scientific misconduct check.pdf
Scientific Editor Work List	25575-Scientific editor work list.pdf